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Familial hypertrophic cardiomyopathy (FHC) is characterized by severe abnormal cardiac muscle growth. The
traditional view of disease progression in FHC is that an increase in the Ca2+-sensitivity of cardiac muscle
contraction ultimately leads to pathogenic myocardial remodeling, though recent studies suggest this may be
an oversimpliﬁcation. For example, FHC may be developed through altered signaling that prevents downstream
regulation of contraction. The mutation L29Q, found in the Ca2+-binding regulatory protein in heart muscle,
cardiac troponin C (cTnC), has been linked to cardiac hypertrophy. However, reports on the functional effects
of this mutation are conﬂicting, and our goal was to combine in vitro and in situ structural and functional data
to elucidate its mechanism of action. We used nuclear magnetic resonance and circular dichroism to solve the
structure and characterize the backbone dynamics and stability of the regulatory domain of cTnC with the
L29Qmutation. The overall structure and dynamics of cTnC were unperturbed, although a slight rearrangement
of site 1, an increase in backbone ﬂexibility, and a small decrease in protein stabilitywere observed. The structure
and function of cTnC was also assessed in demembranated ventricular trabeculae using ﬂuorescence for in situ
structure. L29Q reduced the cooperativity of the Ca2+-dependent structural change in cTnC in trabeculae
under basal conditions and abolished the effect of force-generating myosin cross-bridges on this structural
change. These effects could contribute to the pathogenesis of this mutation.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Heart muscle contraction is regulated by the Ca2+-binding protein
complex troponin. Troponin is a heterotrimeric protein complex that,
with its regulatory partner tropomyosin, is bound to the actin-
containing thin ﬁlaments of the muscle sarcomere at regular intervals
of 7-actin monomers. Cardiac troponin is comprised of: troponin C
(cTnC), the Ca2+-binding subunit; troponin I (cTnI), the inhibitory sub-
unit; and troponin T (cTnT), the tropomyosin binding subunit. During
muscle contraction, Ca2+ is released to the cytosol and binds to the
low afﬁnity Ca2+-binding site (site 2) of the N-terminal domain of
cTnC (cNTnC).With Ca2+-association, cNTnC binds to the switch region
of cTnI (cTnI147–163), which in-turn drags the inhibitory andmobile do-
mains of cTnI off the actin thin ﬁlament. Once cTnI dissociates from
actin, the position of tropomyosin changes, exposing the myosin head
binding sites. Following myosin head attachment, the power stroke
pulls the thin ﬁlament towards the M-line at the centre of the sarco-
mere, causing the cardiomyocyte to shorten and muscle contraction to
occur. Muscle relaxation occurs when cytosolic Ca2+ levels decrease,
resulting in a dissociation of Ca2+ and the switch region of cTnI from
cNTnC. The inhibitory andmobile domains of cTnI bind to actin, trigger-
ing a rearrangement of tropomyosin along the thinﬁlament and a resul-
tant blocking of the myosin-head binding sites. For reviews on the
mechanism of regulation of contraction see Refs [1–3].
Familial hypertrophic cardiomyopathy (FHC) is an inherited dis-
order that is characterized by left ventricle hypertrophy that develops
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into heart failure and arrhythmia [4,5]. Approximately 1 in 500 adults
have FHC, whichmakes it themost common genetic cardiovascular dis-
ease [6,7]. While FHC mutations have been identiﬁed across a wide
range of proteins, more than half of all mutations that cause hypertro-
phy occur in proteins of the sarcomere [5]. As of 2010, 68 mutations in
the troponin complex had been linked to FHC [4]. The ﬁrst mutation as-
sociated with FHC in cTnC was L29Q (cTnC(L29Q)), which was identi-
ﬁed in a patient suffering from left ventricular hypertrophy [8].
In the context of the structure and function of cTnC, the location and
hydrophobic-to-hydrophilic nature of L29Q is provocative. L29 lies at
the start of the defunct Ca2+-binding site in cNTnC (site 1). In the regu-
latoryN-terminal domain of skeletal troponin C (sNTnC), both EF-hands
bind Ca2+ (at sites 1 and 2). Ca2+-binding to sNTnC induces an opening
of the domain that exposes a central hydrophobic patch [9], which
forms its interface with the switch region of troponin I [10]. On the
other hand, as a result of an insertion at residue 28 (V28) and two
amino acid replacements (D29L and D31A), site 1 of cNTnC has lost its
ability to bind Ca2+. Therefore, only one Ca2+ binds to cNTnC (at site
2), and this produces a smaller opening than that observed in sNTnC
[11–13]. In cNTnC, Ca2+ binding is considered to shift the equilibrium
towards the open state [14], but the fully open state is stabilized only
once cTnI147–163 is bound [15]. Shifting the closed-to-open equilibrium
further towards the open state would be a means of increasing Ca2+-
sensitivity of muscle contraction by increasing the afﬁnity of cTnI147-
163 for cNTnC. This mechanism has been exploited by the engineered
L48Q mutation of cNTnC [16,17] and by Ca2+-sensitizing drugs [18],
and since L29 makes hydrophobic interactions with nearby residues
that stabilize the conformation of the loop in site 1 [12,19], replacement
of L29 by glutaminemight be expected to produce a structural perturba-
tion that could alter the function of cTnC.
L29 is also important in the binding of the cardiac speciﬁc N-
terminus of cTnI (cTnI1–32) to cTnC. NMR and cross-linking studies
have indicated that cTnI1–32 comes in close contact with cNTnC,
interacting speciﬁcally with residues in the defunct site 1 (including
L29) [20–23]. cTnC(L29Q) is also insensitive to the Ca2+ desensitization
caused by phosphorylation at residues S22 and S23 in cTnI1–32 [24,25].
Since phosphorylation at these two residues is known to decrease
ﬁber contractility [26], this insensitivity to phosphorylation may be
the pathogenic mechanism of the L29Q mutation.
Biochemical and physiological studies that attempted to charac-
terize the function of cTnC(L29Q) have led to conﬂicting results [24,
25,27–31]. Ca2+ sensitivity of myoﬁlaments reconstituted with
cTnC(L29Q) has been reported to be decreased [24,30], increased [28,
31], or unchanged [27,29]. These discrepancies have been suggested to
be at least partly due to the different model systems used in these stud-
ies (i.e. heterogeneous proteins and/or tissues) [30]; however, the same
range of divergent results have also been reported for isolated protein
components [25,27,31,32]. While the biochemical techniques used in
these reports are as varied as the myoﬁlament preparations, the wide
range of published observations suggests the effect of this mutation
may be subtle or negligible. Indeed, the patient identiﬁed with the
L29Q mutation showed no signs of diastolic or systolic dysfunction [8].
Structural biology has played an indispensible role in facilitating our
understanding of the mechanism by which troponin regulates muscle
contraction [2]. However surprisingly few structures of cTnC with
disease-linked cardiomyopathies have been reported [33,34]. The X-
ray crystal structure of cNTnC(L29Q) bound to eight cadmium ions
was recently solved [34]; however, since cadmium was bound to both
the functional and defunct Ca2+-binding sites of cNTnC(L29Q), it was
difﬁcult to make conclusions on whether L29Q caused any structural
perturbations when compared to the wild-type isoform.
In this study, we combined in vitro solution structural biology by nu-
clear magnetic resonance (NMR) spectroscopy and circular dichroism
(CD) with in situ structural biology by ﬂuorescence for in situ structure
(FISS) to better understand the structural and functional changes asso-
ciated with the L29Q mutation in physiological conditions.
2. Materials and methods
2.1. Protein expression and puriﬁcation
The DNA encoding cNTnC (residues 1–89, with mutations C35S
and C84S) was inserted into the pET-3a expression vector as previ-
ously described [35]. The cysteine-free variant of cNTnC was chosen
for this study to be consistent with the in situ ﬂuorescence experi-
ments (see below). The L29Q mutation was engineered using
cNTnC(C35S C84S) DNA as a template with a site-directed mutagen-
esis kit (QuikChange purchased from Stratagene). The expression
and puriﬁcation of 15N-labeled and 13C,15N-labeled cNTnC(L29Q)
and 15N-labeled cNTnC(C35S,C84S) were as previously described
[32,36].
Two double cysteine mutants of human cTnC(C35S, C84S)3
(E55C/D62C (cTnCC) and E95C/R102C (cTnCE)) with or without
L29Q mutation were produced by site-directed mutagenesis,
expressed in Escherichia coli and puriﬁed as described previously
[37]. Each pair of introduced cysteines was cross-linked with a bi-
functional rhodamine probe (BR) [38]: BR-cTnCC, BR-cTnCE, BR-
cTnC(L29Q)C and BR-cTnC(L29Q)E. C35 and C84 were mutated to
serine residues to prevent non-speciﬁc cross-linking with the native
cysteines.
2.2. Circular dichroism
Circular dichroism (CD) experiments were conducted on a JASCO
model J-820 CD spectropolarimeter at 25 °C. The data were collected
from 260 to 200 nm for the initial spectral measurements and from
230 to 210 nm for stability measurements. All measurements were
made in 1 cm cuvettes with a sensitivity of 50 mDeg, a resolution of
0.5 nm, and a scan speed of 50 nm/min. The cNTnC or cNTnC(L29Q)
concentrations were 2.5 μM. The buffer composition was 10 mM
KH2PO4 (pH 7.1), 100 mM KCl, 1 mM EGTA, and 1 mM CaCl2. For the
urea-induced unfolding experiments, cNTnC or cNTnC(L29Q) was
dissolved in the above buffer with varying concentrations of urea
(0–8 M). Urea was prepared fresh the day of the experiment. The
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where I is the molar ellipticity at 222 nm ([θ]222) at a given urea
concentration ([urea]), I0 is the initial [θ]222 (at 0 M urea), [urea]1/2 is
the concentration of urea required to decrease the CD signal at
222 nm by half, m is the sensitivity towards urea unfolding, y and a
are scaling constants, R is the ideal gas constant, and T is the tempe-
rature in Kelvin. The Gibbs free energy of unfolding (ΔG0F-U) in the
absence of urea was calculated by multiplyingmwith [urea]1/2 [39].
2.3. NMR spectroscopy
All NMR experiments were run on either a Varian Inova 500-MHz or
600-MHz spectrometer equipped with a z-axis pulsed ﬁeld gradient
triple-resonance probes. The pulse sequences for the NMR experiments
run in this studywere in BioPack, the add-on package for vnmrj (Agilent
Technologies). All experimentswere collected at 30 °C. All NMRsamples
had starting volumes of 500 μL. The protein samples were dissolved in
100 mM KCl, 10 mM Imidazole, and 0.2–0.25 mM 2,2-dimethyl-2-
silapentane-5-sulfonate sodium salt (DSS) (Chenomx) with 0.01%
NaN3 in 90% H2O/10% D2O with 8 mM CaCl2 (Fluka). Concentrations of
3 cNTnC(C35S,C84S) and the cTnC(C35S,C84S) will be referred to as cNTnC and cTnC,
respectively.
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cNTnC(L29Q) and cNTnC were approximately 0.3–0.4 mM for all NMR
experiments. The pH was monitored by the chemical shift of imidazole
[40] and was kept constant between 6.6 and 6.7.
2.4. NMR Structure calculation
All NMR data were processed with NMRPipe [41] and visualized
with NMRViewJ [42]. Backbone assignment of 13C,15N-labeled
cNTnC(L29Q) was aided by the semi-automated assignment tool,
Smartnotebook [43]. The NMR experiments and their experimental pa-
rameters collected for the structure determination of cNTnC(L29Q) are
shown in Supplementary Table 1. Backbone dihedral angles were pre-
dicted by TALOS [44] and the HNHA experiment [45] (Supplementary
Fig. 1). χ1 dihedral angles were determined using the HNHB [46] and
HN(CO)HB [47] experiments. χ1 angles were assigned as being either
−60±60°, 180±60°, or 60±60°. Interhelical angles for cNTnC(L29Q)
were predicted using ORBplus [48].
Following chemical shift assignments, the automatedNMR structure
protocol in CYANA [49] was used to aid in the assignment of three-
dimensional NOESY experiments (see Supplementary Table 1). Distance
restraints were calculated in CYANA using an upper limit of 6 Å. Six dis-
tance restraints from X-ray crystallographic data for the Ca2+-chelating
oxygen atoms in site 2 to Ca2+ and two distance restraints betweenD65
and G70 were included to hold the Ca2+-binding loop together. After
the initial calculations by CYANA, the assignments were adjusted man-
ually and in subsequent structure calculations the manual assignments
were kept during the ﬁrst four CYANA calculation cycles, after which
they were open for automatic assignment with the “noeassign” com-
mand of CYANA. 100 structures were calculated, and the 20 conformers
with the lowest target function were used to further reﬁne the struc-
ture. Following the CYANA reﬁnement, peaklists were read back into
NMRViewJ, conﬁrmed manually, and converted into XPLOR-NIH [50,
51] format. The NOEswere calibrated using themedianmethod (median
distance = 3 Å) and exported as an NOE table. The simulated annealing
protocol in XPLOR-NIH was used, with 10,000 high temperature steps
and 6000 cooling steps. The inter-proton distances (derived from NOEs)
were restrained using a soft square-well potential using the sum-
averaging method. Initially, 100 structures were calculated with NOE
and dihedral restraints. The 50 lowest energy structures were then
reﬁned in water with a water box edge length of 18.8 Å [52]. The ﬁnal
deposited ensemble (2N79.pdb) was the 20 lowest energy structures
following water reﬁnement (See Table 2 for the structural statistics).
2.5. 15N backbone relaxation experiments
The T1, T2, and NOE values were recorded for cNTnC(L29Q) and
cNTnC at concentrations of 0.3–0.4 mM on a 500 MHz spectrometer.
The concentrations between samples were kept as similar as possible
since it has been shown that cNTnC will aggregate in a concentration-
dependent manner [53]. All experiments were recorded with the
same experimental parameters: T1 valueswere determined using relax-
ation delays of 10, 50, 100, 200, 300, 400, and 800ms; T2 valueswere ac-
quired using relaxation delays of 10, 30, 50, 70, 90, and 110 ms. The
experiments were acquired in random order to account for ﬁeld drift.
The delay between transients for T1 and T2 experiments was set to 3 s.
The 1H–15N NOE experiments had a delay of 3 s without the proton sat-
uration and when proton saturation was on, it was set to 3 s. Fitting of
the data was done in NMRViewJ [42]. The error was taken as the stan-
dard deviation of the background of the spectra and the peak intensities
weremeasured using the jitter protocol. The expected correlation times
(τm) were calculated based on the relationship:
τm ¼ MW2
whereMW is the molecular weight of the protein expressed in kDa and
τm is in ns [54]. Model-free analysis of the data was done using
Mathematica notebooks [55]. Models were chosen using Akaike's Infor-
mation Criteria (AIC) [56], and Monte Carlo analysis was done on the
chosen model to assess errors [57]. The model-free calculation of the
order parameter (S2) was calculated with the S2-τm, S2-τm-τe, S2-τm-
Rex, S2-τm-τe- Rex, and the two time-scale model (Ss2-Sf2-τm-τs). We
only acquired data from500MHz, however, so if a goodﬁt was obtained
with the relaxation parameters in one of the simpler models it was cho-
sen over the more complex models.
2.6. Reconstitution of TnC into ventricular trabeculae
Ventricular trabeculae from rat right ventricle were prepared as pre-
viously described [37]. Native TnC was partially replaced by incubation
of trabeculae in relaxing solution containing 30 μmol/L BR-TnC over-
night at 4 °C. The fraction of TnC replaced by BR-TnC was about 80%
[58]. Following incubation, the demembranated trabeculae were
mounted via aluminum T-clips between a force transducer and a ﬁxed
hook in a 60 μL trough containing relaxing solution. The sarcomere
length was set to 2.1 μm. The experimental temperature was 20–22 °C.
Experimental solutions contained 25 mM imidazole, 5 mMMgATP,
1 mM free Mg2+, 10 mM EGTA (except pre-activating solution),
0–10mM total calcium, 1 mMdithiothreitol and 0.1% (v/v) protease in-
hibitor cocktail (P8340, Sigma). Ionic strength was adjusted to 200 mM
with potassium propionate; pH was 7.1 at 20 °C. The concentration of
free Ca2+ was calculated using the program WinMAXC V2.5 (http://
web.stanford.edu/~cpatton/maxc.html). The calculated free [Ca2+]
was in the range 1 nM (pCa 9) to 32 μM (pCa 4.5). In pre-activating so-
lution, [EGTA] was 0.2 mM and no calcium was added. When required,
25 μMblebbistatin (B0560, Sigma)was added from a 10mMstock solu-
tion in DMSO.
2.7. Measurement of TnC helix orientation by polarized ﬂuorescence
Fluorescence polarization measurements were performed as previ-
ously described [37]. Brieﬂy, a central 0.5-mm segment of a trabecula
was brieﬂy illuminated from below with 532 nm light polarized either
parallel or perpendicular to the trabecular axis. BR ﬂuorescence at
610 nm was collected both in line with the illuminating beam and at
Table 1
Interhelical angles of cNTnC.
AB angle (°) CD angle (°) Ref.
Experimental measurementsa
cNTnC(WT) 134 ± 3 118 ± 4 [12]
cNTnC 142 ± 3 109 ± 4 [11]
cNTnC(WT)-cTnI147–163 102 ± 4 95 ± 6 [15]
ScNTnC 130 ± 3 112 ± 5 [61]
cNTnC(L29Q)b 139 ± 5 122 ± 7 –
ORBplus calculationsc
cNTnC(L29Q)b 143 118 –
cNTnC(L29Q)-cTnI1–29 143 117 [32]
cNTnC(L29Q)-cTnI1–29PP 143 118 [32]
cNTnC(L29Q)-cTnI147–163 106 85 [32]
cNTnC(L29Q)-cTnI147–163-cTnI1–29 109 87 [32]
cNTnC(L29Q)-cTnI147–163-cTnI1–29PP 111 93 [32]
cNTnC 144 117 [11]
cNTnC-cTnI1–29 144 116 [32]
cNTnC-cTnI1–29PP 145 117 [32]
cNTnC-cTnI147–163 106 93 [32]
cNTnC-cTnI147–163-cTnI1–29 105 91 [32]
cNTnC-cTnI147–163-cTnI1–29PP 104 91 [32]
a Residues 17–26 and 40–46 for the AB interhelical angle and 54–62 and 75–83 for the
CD interhelical angle. Angles were calculated using interhlx (K. Yap, University of
Toronto).
b This work.
c Calculated using chemical shifts from residues 27–40 for the AB interhelical angle and
64–74 for the CD interhelical angle. The amide chemical shifts of residue 29were not used
in the calculation for cNTnC(L29Q).
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90° to both the illuminating beam and the trabecular axis. The intensi-
ties of the parallel and perpendicular polarization components of each
collected beam were used to calculate the order parameters. The order
parameters bP2N and bP4N describe the orientation of the BR dipole,
and therefore that of the helix to which it is attached, with respect to
the trabecular or thin ﬁlament axis [59].
Each trabecular activation was preceded by a 1 min incubation in
pre-activating solution. Isometric force and ﬂuorescence intensities
weremeasured after steady-state force had been established in each ac-
tivation. Maximum force was recorded before and after each series of
activations at submaximal [Ca2+]. If the maximum force decreased by
N15%, the trabecula was discarded. The dependence of force and bP2N
on [Ca2+] was ﬁtted to data from individual trabeculae using non-
linear least-squares regression to the Hill equation:
Y ¼ 1
1þ 10nH pCa−pCa50ð Þ
where pCa50 is the pCa corresponding to half-maximal change in Y, and
nH is theHill coefﬁcient. All values are given asmean± standard error of
Fig. 1. Chemical shift perturbations caused by L29Q in cNTnC. (A) An overlay of the 1H,15N HSQC spectra of cNTnC (dark blue) and cNTnC(L29Q) (light blue). (B) The chemical shift
differences (Δδ) between cNTnC and cNTnC(L29Q) as a function of sequence (and secondary structure). Δδ was calculated using the formula: Δδ= ((ΔδH)2 + (0.2* ΔδH)2)1/2. (C and
D) Residues that underwent Δδ larger than the mean are shown as spheres (Q29 is shown in red) on the cartoon representation of cNTnC(L29Q). (D) A 180° rotation about the y-axis
of ﬁgure (C).
Table 2
Ca2+-dependence of force and the cTnC orientation parameter bP2N.
BR-cTnCC +25 μM blebbistatin BR-cTnCC (L29Q) +25 μM blebbistatin BR-cTnCE +25 μM blebbistatin BR-cTnCE (L29Q) +25 μM blebbistatin
(n = 4) (n = 4) (n = 5) (n = 6)
Force
pCa50 5.64 ± 0.02 5.55 ± 0.03 # 5.67 ± 0.02 5.63 ± 0.02 NS
nH 3.35 ± 0.18 2.88 ± 0.31 NS 3.66 ± 0.29 3.34 ± 0.41 NS
bP2N
pCa50 5.72 ± 0.01 5.65 ± 0.01 * 5.69 ± 0.01 NS 5.68 ± 0.01 ns 5.69 ± 0.01 5.63 ± 0.01 * 5.67 ± 0.01 NS 5.67 ± 0.02 ns
nH 4.14 ± 0.25 2.66 ± 0.34 * 2.98 ± 0.14 # 2.29 ± 0.10 * 4.20 ± 0.18 3.17 ± 0.27 * 3.37 ± 0.23 # 2.46 ± 0.18 *
at pCa 6.4 0.106 ± 0.004 0.098 ± 0.004 * 0.098 ± 0.001 NS 0.092 ± 0.001 * 0.287 ± 0.008 0.296 ± 0.008 * 0.287 ± 0.008 NS 0.301 ± 0.007 *
at pCa 4.5 0.007 ± 0.009 0.020 ± 0.008 * 0.003 ± 0.003 NS 0.020 ± 0.002 * 0.190 ± 0.005 0.232 ± 0.006 * 0.178 ± 0.008 NS 0.231 ± 0.006 *
Mean± SEM. pCa50 and nH are ﬁtted parameters of Hill equation (seeMethods andMaterials). Comparisons: with and without L29Qmutation (t test, two-tailed; NS P N 0.05; # P b 0.05);
before and after addition of blebbistatin (paired t test, two-tailed; ns P N 0.05; * P b 0.05).
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the mean except where noted, with n representing the number of
trabeculae.
3. Results
3.1. Structure of cNTnC(L29Q)
Initially, NMR chemical shift data were used to predict the global
structure to assess whether L29Q altered the closed-to-open equilibri-
um of cNTnC. We compared the chemical shifts of cNTnC(L29Q) with
the chemical shifts from a panel of cNTnC structures using the program
ORBplus [48] (Supplementary Fig. 2). Principal component analysis has
identiﬁed the amide chemical shifts of residues that lie in the two EF-
hand loops (that include the Ca2+-binding sites 1 and 2) as being the
most predictive of cNTnC conformation [48]. The conformation of
cNTnC(L29Q) was predicted based on residues 27–40 for the AB
interhelical angle (angle between A and B helices) and residues 64–74
for the CD interhelical angle (angle between C and D helices). The closer
the angle is to 180°, the more closed the structure is, whereas values
closer to 90° represent a more open structure. The AB interhelical
angle was predicted to be 143° and the CD interhelical angle was pre-
dicted to be 118° (Table 1). These interhelical angles are very close to
those of cNTnC, indicating that the global structure of cNTnC(L29Q) is
unperturbed by the mutation. Indeed, when the difference between
amide chemical shifts from cNTnC and cNTnC(L29Q) are mapped on
the structure of cNTnC (Fig. 1), it is evident that most of the perturbed
chemical shifts are in the immediate vicinity of themutation, indicating
that a major structural change is unlikely. Therefore, we turned to high-
resolution NMR spectroscopy to look for small structural perturbations
caused by L29Q.
The NMR structure of cNTnC(L29Q)was calculated using NMR spec-
troscopy (Fig. 2). 1692 distance restraints and 175 dihedral restraints
(ϕ/ψ/χ1) were used in the reﬁnement of the structure (structural
statistics in Supplementary Table 2). The backbone Root-Mean-Square
Deviation (RMSD) for residues 3–19 and 52–85 was 0.94 ± 0.18 Å.
Therewere noϕ/ψ/χ1 violations greater than 5°, nodistance restraint vi-
olations N0.3 Å, and all theϕ/ψ angleswere in the allowed regions of the
Ramachandran plot. As with cNTnC, cNTnC(L29Q) contained 5 α-
helices (N, A, B, C, D). Therewere also two small β-strands, one between
helices A and B (in site 1) and one between helices C and D (in site 2),
which come together to form an antiparallel β-sheet.
The three-dimensional tertiary structure of cNTnC(L29Q) was
solved using distance restraints from the nuclear overhauser enhance-
ment (NOE) spectroscopy (NOESY) NMR experiment. The NOESY ex-
periment measures proton-proton distances within 5–6 Å, with closer
proton pairs leading to stronger NOEs than nuclei that are farther
apart [60]. The interhelical angles of cNTnC(L29Q), and thus its tertiary
structure, depend on a few crucial interhelical NOEs. Fig. 2C and D
shows a network of NOEs that were essential in determining the struc-
ture of cNTnC(L29Q). The β-methyl protons of A23 (on the A-helix)
were found to make NOEs with the ζ proton of F27 (also on the A
helix), as well as with the methyl protons of V44 and L48. These NOEs
highlight the closed structure of cNTnC(L29Q).
3.2. Comparison of the structure of cNTnC(L29Q) with cNTnC and ScNTnC
To identify whether a structural change was associated with the
L29Q mutation, the structure of cNTnC(L29Q) was superimposed on
that of cNTnC (Fig. 3A). The structures were aligned by their secondary
structural elements (Cα atoms of residues: 5–10 (N Helix), 15–27 (A
Helix), 40–48 (B Helix), 54–64 (C Helix), 74–86 (D Helix), and 35–37
and 71–73 (β-sheet)). The root-mean-square deviation (RMSD) was
1.29 Å, indicating little difference between the structures. The structure
of cNTnCwas characterized using the AB andCD interhelical angleswith
the program interhlx (K. Yap, University of Toronto) with residues 17–
26 and 40–46 for the AB interhelical angle and residues 54–62 and
Fig. 2. Structure of cNTnC(L29Q). A. The structure of cNTnC(L29Q) is shown in cartoon representation (Ca2+ ion bound in site II as a black sphere) with theD helix pointed out of the page.
B. The structure rotated by 90°. C. A close-up of the AB interhelical interface. Several of the key residues that make of this interface are shown in stick format (residues A23, F27, V44, and
L48). D. NOE evidence for the closed conformation of cNTnC(L29Q). A slice from the 13C-HSQCNOESY spectrum highlighting the NOEs made by the methyl of A23.
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75–83 for the CD interhelical angle. The AB interhelical angle for
cNTnC(L29Q) was 139 ± 5°, and the CD interhelical angle was 122 ±
7°, both of which are very close to the ORBplus prediction (143° and
118°, respectively) and to cNTnC (142 ± 3° and 109 ± 4°, respectively)
(Table 1).
As trout cNTnC (ScNTnC) also containsQ29 in site 1, the structures of
cNTnC(L29Q) and ScNTnC [61]were compared. The structural elements
deﬁned above were aligned between cNTnC(L29Q) and ScNTnC
(Fig. 3A) and the RMSD was measured as 1.37 Å, not much different
than that between cNTnC(L29Q) and cNTnC. This observation is sup-
ported by the interhelical angles (AB interhelical angle = 130 ± 3°
and the CD interhelical angle = 112 ± 5°), indicating that Q29 does
not impart a large-scale structural perturbation in the backbone of
cNTnC.
To investigate whether Q29 has an effect on local structure, the con-
formation of sites 1 and 2 was examined more closely. Both sites were
inspected since it has been shown that they are structurally and ther-
modynamically coupled [19]. The site 1 sequence alignment of
cNTnC(L29Q), cNTnC, and ScNTnC is given in Fig. 2B. The structures
were aligned at residues 15–27 (helix A) and 41–48 (helix B) and the
orientation of the site 1 loop was contrasted between the structures
(Fig. 3C). The Cα RMSD for the alignment of cNTnC(L29Q) with cNTnC
was 3.20 Å and the Cα RMSD for the alignment of cNTnC(L29Q) with
ScNTnC was 1.77 Å. On the other hand, when the structures were
aligned at residues 54–64 (helix C) and 76–79 (helix D), the orientation
of the site 2 loop was similar between all three isoforms (Cα RMSD for
the alignment with cNTnC was 1.94 Å and the Cα RMSD for the align-
ment with ScNTnC was 1.78 Å). Therefore, although there is no global
structural change induced by L29Q, there appears to be a minor pertur-
bation limited to the direct vicinity of the mutation.
3.3. Dynamics and stability of cNTnC(L29Q) and cNTnC
To substantiate the small structural perturbation caused by L29Q,
the backbone dynamics of cNTnC(L29Q) were compared with those of
cNTnC. The 15N NMR relaxation parameters T1, T2, and NOE depend on
the internal motions of the NH bond vector as well as on the overall
tumbling, or rotational diffusion, of the protein and they can provide
atomic level information on the dynamics of the protein. T1, T2, and
NOE were measured for both cNTnC and cNTnC(L29Q) at 500 MHz
(Fig. 4). Consistent with the lack of major structural changes, the NMR
relaxation parameters did not vary signiﬁcantly. The average relaxation
Fig. 3.Comparison of the structure of cNTnC(L29Q)with cNTnC and ScNTnC. A. The structure of cNTnC (PDB: 2CTN, gray) and ScNTnC (PDB: 1R2U, orange)were alignedby their secondary
structural elements (residues 5–10,15–27, 35–37, 40–48, 54–64, 71–73, and 74–86) to cNTnC(L29Q) (slate). B. Sequence of site 1 for cNTnC (gray), ScNTnC (orange), and cNTnC(L29Q)
(slate). C. The overlay of the average structures of cNTnC(L29Q) with cNTnC (left) and ScNTnC (right) (helices are represented as cylinders). The Cα of residue 29 is shown as a sphere
(radius set to 0.5 Å). The structures were aligned to the backbone of residues 15–27 and 41–48 and the RMSD of the Cα in site 1 (residues 28–40) was determined to be 3.20 Å
(cNTnC) and 1.77 Å (ScNTnC). All structures are shown in cartoon representation and Ca2+ ions are depicted as black spheres.
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parameters for cNTnCwere: T1= 440± 70ms, T2= 139± 69ms, and
NOE = 0.68 ± 0.39 and the average relaxation parameters for
cNTnC(L29Q) were: T1 = 415 ± 63 ms, T2 = 144 ± 53 ms, and
NOE = 0.70 ± 0.27. The values measured here were similar to those
previously reported for cNTnC(wt), (T1 = 440 ± 106 ms, T2 = 166 ±
82 ms, and NOE = 0.57 ± 0.27) [19]. Correlation times (τm) for
cNTnC and cNTnC(L29Q) were calculated assuming the tumbling to be
isotropic [19] based on T1 and T2 for residues with NOEs N 0.65, and
were 5.64 ns and 5.26 ns for cNTnC and cNTnC(L29Q), respectively.
These values are slightly higher than the theoretical τm (cNTnC:
5.09 ns; cNTnC(L29Q): 5.10 ns), which is most likely the result of
concentration-dependent aggregation [53]. This small amount of ag-
gregation is not expected to have a signiﬁcant effect on the calculation
of the order parameter (S2) [19]. Indeed, the average S2 of cNTnC was
0.834 ± 0.121 and the average S2 for cNTnC(L29Q) was 0.852 ±
0.108. Therefore, as was the case for the global conformation of
cNTnC(L29Q) and cNTnC, both proteins also have similar overall back-
bone dynamics.
Sites 1 and 2were comparedmore closely to look for small localized
perturbations, since these two sites are thermodynamically coupled
[19]. The backbone dynamics of site 1 were very similar between
cNTnC and cNTnC(L29Q) (Fig. 5); the average S2 was 0.844 ± 0.077
for cNTnC and the average S2was 0.841±0.077 for cNTnC(L29Q).How-
ever, there were local differences, primarily at residues near the muta-
tion site. The order parameter of residue 29 indicated that Q29 is more
ﬂexible than L29 (S2= 0.740± 0.020 versus 0.841± 0.027, respective-
ly) and the combined ΔS2 of V28, Q29 and G30 were decreased by
0.22 ± 0.09 when compared with those of V28, L29, and G30. There
was no major change in the dynamics of site 2, which is consistent
with the structural alignment presented in the previous section. The av-
erage S2 for cNTnC was 0.872 ± 0.052 and for cNTnC(L29Q) it was
0.877± 0.051. Taken together, these data suggest that a localized struc-
tural effect of L29Q leads to an increase in the ﬂexibility of part of site 1.
To determine whether this small change in structure and ﬂexibil-
ity of site 1 translated to a change in stability, we used circular di-
chroism (CD) to follow the urea-induced denaturation of cNTnC or
cNTnC(L29Q). Unfolding was monitored by measuring the CD signal
at 222 nm (wavelength indicative of helicity) as a function of urea
concentration (Supplementary Fig. 3). The [urea]1/2 values are very
similar: 4.6 ± 0.1 M and 4.8 ± 0.1 M for cNTnC and cNTnC(L29Q), re-
spectively, but the m values are slightly less for cNTnC(L29Q): 4.1 ±
0.1 versus 3.3 ± 0.4. This translates into a higher Gibbs free energy of
unfolding (ΔG0F-U) for cNTnC (ΔG0F-U = 18.9 ± 0.6 kJ mol−1) than
cNTnC(L29Q) (ΔG0F-U = 15.8 ± 1.9 kJ mol−1). Thus, in addition to
altering the structure and dynamics of site 1, the L29Q mutation
also slightly decreases the stability of cNTnC.
3.4. Prediction of the structure of cNTnC(L29Q) bound to cTnI
Although no large conformational changes were observed for
cNTnC(L29Q) in comparison with cNTnC, it is possible that L29Q alters
the conformation of cNTnC in the presence of its binding partners. For
example, a recent computational study [31] proposed that while the
structure of cNTnC-cTnI147–163 (as deﬁned by the AB interhelical
angle) was sensitive to the pseudo-phosphorylated state of cTnI1–32
(represented as S22D, S23D), that of cNTnC(L29Q)-cTnI147–163 was
not. Moreover, that study suggested that cNTnC(L29Q) is more open
than cNTnC; an AB interhelical angle difference of 5° when bound to
cTnI1–32 and 13°when bound to cTnI1–32(S23D,S24D)was calculated. To in-
vestigate this possibility, we used ORBplus to predict the conformation
of cNTnC and cNTnC(L29Q) based on theNMR chemical shifts published
in Baryshnikova et al. [32] (Table 1). The AB and CD interhelical angles
were calculated for cNTnC(L29Q) and cNTnC in the following com-
plexes: cNTnC, cNTnC-cTnI1–29, cNTnC-cTnI1–29PP (phosphorylated at
S22, and S23), cNTnC-cTnI147–163-cTnI1–29, and cNTnC-cTnI147–163-
cTnI1–29PP. In contrast with the computational study [31], we found
no effect of cTnI1–29 (or cTnI1–29PP) on either the AB or CD interhelical
angles. Furthermore, in the presence of cTnI1–29 (or cTnI1–29PP), we
found that the AB angle of cNTnC(L29Q) is slightly more closed than
that of cNTnC (109–111° versus 105–104°, respectively). Nevertheless,
the angular changes are small, which is consistent with our interpreta-
tion that the small chemical shift perturbations induced by cTnI1–29
binding are likely to be the result of a local electrostatic interaction rath-
er than a large conformational change of cNTnC [32].
Fig. 4. A comparison of T1, T2, NOE, and S2 for cNTnC(L29Q) (open symbols) and cNTnC
(closed symbols). Relaxation data were collected at a magnetic ﬁeld strength of 11.7
Tesla (1H larmor frequency of 500 MHz). Error bars denote SD.
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3.5. Functional and structural impact of cTnC(L29Q) in cardiac muscle cells
The in vitro characterization of cNTnC(L29Q) by NMR spectroscopy
indicated that the global conformation of cNTnC was not altered by
the mutation, suggesting that this cardiomyopathy-causing mutation
may exert its effect by altering the protein-protein interactions in the
downstream signaling pathway. The structural and functional impact
of L29Q was therefore investigated in demembranated ventricular tra-
beculae, in which the native assembly and interactions of the proteins
are largely preserved. The in situ orientation of cTnC was determined
using TnC mutants with BR attached along either the C helix (BR-
cTnCC), adjacent to the regulatory Ca2+-binding site, or the E helix in
the C-lobe (BR-cTnCE) (Supplementary Fig. 4). Maximum Ca2+-
activated isometric force after introduction of cTnC(L29Q) was
31 ± 4 mN mm−2 (SEM, n = 11) for BR-cTnC(L29Q)C and 41 ±
5 mN mm−2 (n = 10) BR-cTnC(L29Q)E. These values are not statisti-
cally different (P N 0.05) from those measured after replacement of
native TnC by wild-type BR-cTnCs, 38 ± 4 mN mm−2 (n = 12) for
BR-cTnCC and 36 ± 5 mN mm−2 (n = 10) BR-cTnCE. Thus the intro-
duction of L29Q did not signiﬁcantly affect the maximum Ca2+-
activated force, in agreement with previous reports [27–30]. Addi-
tionally, the slack length of the preparations after exchange of BR-
TnC was the same as that without TnC exchange (sarcomere length
1.9 μm).
The orientation of the BR ﬂuorescence dipole, and thus of the C or E
helix of cTnC to which it was attached, was determined from the polar-
ization of ﬂuorescence from trabeculae containing BR-cTnC. The polar-
ized ﬂuorescence intensities were used to calculate the order
parameter bP2N that describes the orientation of the BR dipole [59].
bP2N would be +1 if all the probes were parallel to the trabecular
axis, and−0.5 if they were all perpendicular.
The effect of the L29Q mutation on relationships between force or
cTnC orientation (bP2N) and free calcium concentration in the pCa
(− log[Ca2+]) range from 9.0 (relaxed) to 4.5 (full activation) was in-
vestigated using calcium titrations (Fig. 6). The data for both force
and bP2N for the C helix probe in the absence of L29Q (Fig. 6
A) were well ﬁtted by the Hill equation, over the full range of pCa.
However, in the presence of L29Q (Fig. 6B) bP2N for the C helix
probe showed an additional high-afﬁnity component in the sub-
threshold range of [Ca2+], as observed for the E helix probe in both
the absence ([37], Fig. 6 C) and presence of L29Q (Fig. 6D). The origin
of the high afﬁnity component is unknown, but since it is conﬁned to
the region in which no active force is generated, we conﬁned all the
Hill equation ﬁts of bP2N data to the region pCa 6.4 to pCa 4.5, in
which they were well described by this equation (Fig. 6, dashed
lines).
The effects of the L29Q mutation on the Hill parameters for both
force and the orientation changes of the C and E helices of cTnC are sum-
marized in Table 2. Here pCa50, the pCa for half-maximal change in ei-
ther force or b P2N, is a measure of Ca2+ sensitivity; nH, the Hill
coefﬁcient, describes the steepness of the Ca2+ dependence and is a
measure of cooperativity of the Ca2+-dependent change. The L29Qmu-
tation was associated with a small but signiﬁcant decrease in pCa50 for
force in the trabeculae containingBR-TnCC, but there was no signiﬁcant
change for those containing BR-TnCE, and no signiﬁcant effect on nH,
although the mean value of the latter was lower in the presence of
L29Q. Much clearer effects were seen in the ﬁtted parameters for
bP2N, which is more reproducible between batches of trabeculae.
The L29Q mutation had no signiﬁcant effect on pCa50 for either the
C or E helix probes, but in both cases it reduced nH, indicating a de-
crease in the cooperativity of the structural changes associated with
calcium activation. The overall amplitude of the structural changes
between pCa 6.4 and 4.5 was not affected by the presence of the
L29Q mutation, consistent with the absence of a major change in
the three-dimensional structure of the protein in the NMR results
presented above.
3.6. cNTnC(L29Q) abolishes the myoﬁlament response to force generating
myosin heads
Strongly boundmyosin cross-bridges that are formed in the absence
of ATP (in rigor) can contribute to thin ﬁlament activation [62–64], and
force-generating myosin cross-bridges in the presence of ATP can in-
crease the Ca2+ sensitivity of cTnC structural changes [37]. Further-
more, a recent report suggested that force-generating myosin heads
are responsible for a Ca2+-sensitizing effect on the opening of cNTnC
[65]. These results indicate that force-generating myosin heads might
stabilize the interaction between the exposed hydrophobic patch of
cNTnC and the switch region of cTnI. We used 25 μM blebbistatin
to abolish active force and thereby determine the effect of force-
generating myosin heads on cTnC structure and calcium activation in
the presence of the L29Q mutation. Inhibition of active force by
blebbistatin reduced the amplitude of the changes in the orientation
of both the C and E helices of cTnC as reported by bP2N, in both the pres-
ence and absence of the L29Qmutation (Fig. 6 and Table 2). Blebbistatin
also signiﬁcantly (P b 0.05) reduced the steepness of the Ca2+ depen-
dence (nH, Table 2) independently of the presence of L29Q. In wild
type cTnC, blebbistatin decreased pCa50 for both the C and E helix orien-
tation (Table 2; P b 0.05, paired comparison), as reported previously
[37]. Strikingly, L29Q abolished this effect of blebbistatin on pCa50 for
the orientation changes of both helices; the effect of force-generating
cross-bridges on the structural changes in cTnC associated with calcium
activation is abolished by the L29Q mutation.
4. Discussion
FHC is the most commonly inherited form of cardiovascular disease
[6,7], and several FHC-related mutations have been identiﬁed in cTnC,
including: L29Q [8], A8V, C84Y, E134D, D145E [66], Q122AfsX30 [67],
and A31S [68]. Given that L29Q was the ﬁrst FHC-linked mutation
discovered in cTnC, it has garnered the most attention; however it
remains unclear whether the mutation is pathogenic or simply a rare
polymorphism. The only clinical instance of this mutation was in a 60-
year-old patient [8], so it is likely that if L29Q is indeed pathogenic,
the physiological effect is subtle. In this study, we attempted to charac-
terize the in vitro and in situ structure and function of cTnC(L29Q) to un-
derstand its potential pathogenesis.
4.1. In vitro structure, dynamics and stability of cNTnC(L29Q)
NMR spectroscopy was used to solve the structure of the Ca2+-
bound conformation of cNTnC(L29Q). The overall structure was unper-
turbed by the mutation, resulting in an essentially closed conformation
of cNTnC (Fig. 2 and Table 1). Closer inspection of the residues in the de-
funct site 1 revealed a slight perturbation the backbone atoms when
compared to cNTnC (Fig. 3). Interestingly, the orientation of the site 1
loop ismore similar to trout cNTnC (ScNTnC), which also contains a glu-
tamine at residue 29. As a compensatory mechanism for its lower phys-
iological temperature, the Ca2+ afﬁnity of trout cardiac troponin C
(ScTnC) is higher than themammalian isoform [69,70]. Despite the dra-
matic difference in Ca2+-afﬁnity, the sequences of the N-domain of
ScTnC (ScNTnC) and cNTnC have only ﬁve amino acid differences, four
of which have been implicated as being primarily responsible for the in-
creased Ca2+ sensitivity: D2N, V28I, L29Q, and G30D [71]. One explana-
tion for the change in structure may be that the mutation from a
hydrophobic residue to a hydrophilic one destabilizes hydrophobic
packing surrounding the residue. Indeed, this is supported by the in-
creased ﬂexibility of Q29 compared to L29 as indicated by the NMR re-
laxation measurement (Fig. 5). Urea-induced unfolding measurements
indicated that the L29Q mutation caused a slight decrease in ΔG0F-U,
which is consistent with a local structural destabilization of Q29.
Recently, the Cd2+-bound X-ray structures of several variants of
cNTnC, including cNTnC(wt), cNTnC(L29Q), and cNTnC(NIQD) (D2N,
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V28I, L29Q, and G30D) have been published [34]. Although the numer-
ous Cd2+ molecules in the structures, including Cd2+ bound to site 1,
made the physiological relevance of these structures difﬁcult to inter-
pret, the authors also noted a small perturbation of 0.5 Å in the back-
bone of L29Q and 1.0 Å in the backbone of cNTnC(NIQD) in site 1 that
is consistent with our ﬁndings. Together these data indicate that while
L29Q does not drastically alter the structure of cNTnC, it does cause a
small local rearrangement of site 1, which may alter its function,
perhaps through hampering its interactionwith other binding partners,
such as cTnI (discussed below).
One limitation of the current study is that the structure does not in-
clude the C-domain of cTnC; therefore, we cannot rule out the possibil-
ity that L29Q elicits a structural perturbation in the C-domain and/or in
the relative orientation between the N- and C-domains of cTnC in vitro.
Indeed, an NMR study investigating the inter-domain conformation of
cTnC indicated that while the two domains of cTnC are ﬂexible, they
Fig. 5. A comparison of T1, T2, NOE, and S2 for residues in sites 1 and 2 of cNTnC(L29Q) (open symbols) and cNTnC (closed symbols). Relaxation data were collected at a magnetic ﬁeld
strength of 11.7 Tesla (1H larmor frequency of 500MHz). Residues 37, 38, 39, and 40were ﬁt with the S2-τm-Rexmodel. The S2 for residue 29 is highlighted by a box. Error bars denote SD.
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preferentially adopt a compact structure [72] that is consistent with the
X-ray structure of the cardiac troponin complex [73]. Although a long-
range structural effect of L29Q in vitro is possible, our FISS data indicate
that L29Q does not cause a signiﬁcant perturbation on the orientation of
the C-domain of cTnC in situ (Fig. 6 and Table 2).
4.2. Functional and structural impact of cTnC(L29Q) in cardiac muscle cells
To complement the studies at the isolated protein level described
above, we used FISS to investigate the effects of L29Q on the structure
of cTnC in its native sarcomere environment in rat ventricular trabecu-
lae. The introduction of L29Q did not signiﬁcantly affect maximum ac-
tive force in this preparation, in agreement with previous reports
[27–30]. L29Qwas associated with a signiﬁcant decrease in the calcium
sensitivity of active force asmeasured by pCa50 in trabeculae containing
cTnC labeledwith the C-helix probe, but the corresponding decrease for
the E-helix probewas not signiﬁcant at the 5% level. For both probes the
mean value of the cooperativity parameter nH for forcewas lower in the
presence of L29Q but again the differenceswere not signiﬁcant at the 5%
level. Thus the present results cannot be regarded as conclusive on the
effect of L29Q on the Ca2+-dependence of active force, perhaps because
this parameter depends on many factors downstream of cTnC and
exhibits relatively high sample-to-sample variability. We therefore fo-
cused on the orientation changes of cTnC during Ca2+ activation,
which can be measured with greater reproducibility.
The structural changes of cTnC during Ca2+ activation were deter-
mined from the polarization of ﬂuorescence from trabeculae containing
BR-labeled cTnC with the probe attached along either the C helix, adja-
cent to the regulatory Ca2+-binding site, or the E helix, in the IT arm of
the troponin complex. The polarized ﬂuorescence intensities were used
to calculate the order parameter bP2N that describes the orientation of
the BR dipole [59]. The Ca2+-dependence of the bP2N changes was de-
scribed using the Hill equation, which gave a good ﬁt to the C helix
probe data over the full range of pCa (Fig. 6 A). However, in the presence
of L29Q, bP2N for the C helix probe showed an additional high-afﬁnity
component in the sub-threshold range of [Ca2+] (Fig. 6 B), as observed
for the E helix probe in both the absence ([37], Fig. 6 C) and presence of
L29Q (Fig. 6D). This additional componentmay be associatedwith Ca2+
binding to the high-afﬁnity Ca2+/Mg2+ sites in the C-terminal domain
of cTnC. Since this component is observed at [Ca2+] values below the
physiological range, at which no active force is generated, we mini-
mized its effect on the ﬁtted Hill equation parameters by conﬁning all
the ﬁts of the bP2N data to the pCa region 6.4 to 4.5.
The overall amplitude of the structural changes in cTnC in thepCa re-
gion 6.4 to 4.5 was not affected by the L29Q mutation, which is consis-
tent with the NMR results showing that L29Q does not markedly alter
the structure of cNTnC. The L29Q mutation had no signiﬁcant effect on
pCa50 for either the C or E helix probe. This implies that, although
cNTnC(L29Q) adopts a similar conformation as ScNTnC, it does not in-
crease Ca2+-sensitivity. This might be due to competing effects of the
L29Qmutation on Ca2+ sensitivitymediated by the interaction between
cNTnC and the cardiac speciﬁc N-terminal region of cTnI (see below).
Force-generating myosin heads can increase the Ca2+ sensitivity of
structural changes in cTnC in the presence of ATP [37], possibly by pro-
moting the opening of cNTnC [65]. The present study conﬁrmed previ-
ous results [36] showing that inhibition of active force by blebbistatin
reduced both the amplitude and the Ca2+ sensitivity of the structural
changes in cTnC (Fig. 6 and pCa50 in Table 2).
The present study showed that L29Q mutation reduced the steep-
ness (nH) of the cTnC orientation changes induced by Ca2+ (Table 2),
indicating a decrease in the cooperativity of the Ca2+-dependent struc-
tural changes. nH was also reduced by adding blebbistatin, both in the
presence and absence of the L29Q mutation, an effect that was not sta-
tistically signiﬁcant in our previous study of the wild-type protein [37].
The difference is probably related to the use of a different calcium titra-
tion protocol in that study, in which each activation was initiated sepa-
rately with relaxing solution, in contrast with the step-wise increments
of [Ca2+] used in the present study. The lower nH observed in the previ-
ouswork suggests that the cooperative activation of cardiacmuscle cells
may be inﬂuenced by the prior state of activation. In the present study
Fig. 6. Ca2+-dependence of bP2N (open symbols) and force (ﬁlled circles) in trabeculae containing A. BR-cTnCC, B. cTnC(L29Q)C, C. BR-cTnCE and D. BR-cTnC(L29Q)E. Normal trabeculae
activation (blue circles) and activation with force inhibition by 25 μM blebbistatin (red squares). Dashed lines are ﬁts of Hill equation to bP2N and force, respectively. Error bars denotes
SEM for n = 4–6 trabeculae.
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any such effect was avoided by using the same protocol for the control
and L29Q measurements.
In the presence of the L29Q mutation, inhibition of active force by
blebbistatin reduced both the amplitude of the orientation changes in
cTnC and the steepness of Ca2+ dependence, as in wild-type cTnC.
However the L29Q mutation abolished the effect of blebbistatin, and
therefore the effect of force-generating cross-bridges on the Ca2+ sen-
sitivity of the structural changes (Table 2).
Taken together, the present results show that the L29Qmutation re-
duces both the cooperativity of Ca2+-dependent structural changes in
cTnC and the modulation of its Ca2+ sensitivity by force-generating
cross-bridges. These effects may be mediated by an altered interaction
between cNTnC and the cardiac speciﬁc N-terminal region of cTnI, as
discussed below.
4.3. cTnC(L29Q) alters the interaction between cNTnC and cTnI1–32
There have been numerous reports showing that the N-terminal re-
gion of cTnI interacts with cNTnC, both using fragments of cTnI [21–24,
32,74] and in thewhole troponin complex [20].When cTnI is phosphor-
ylated at S22 and S23, its interaction with cNTnC is weakened [21–24,
32] and Ca2+-sensitivity is reduced (reviewed in [26]). An NMR study
showed that the amide chemical shift of L29 is signiﬁcantly perturbed
when cTnI is phosphorylated, indicating that it plays a role in binding
cTnI1–32 [23]. However, the interaction of the N-terminus of cTnI with
cNTnC is weakened in the presence of the L29Q mutation, regardless
of its phosphorylation state [24,32]. This suggests that the pathogenesis
of the L29Q may be manifested through an impaired interaction with
the N-terminus of cTnI.
In the present study, amide chemical shifts weremeasured in a vari-
ety of cNTnC-cTnI and cNTnC(L29Q)-cTnI complexes (Table 1). Neither
cTnI1–29 nor cTnI1–29PP caused major changes in the chemical shifts
(and hence in the predicted conformation) of cNTnC or cNTnC(L29Q).
These results are in contrast to those of a computational study of a
model of the ternary complex of cNTnC-cTnI147–163-cTnI1–32 [31]. In
that study, the AB inter-helical angle of cNTnC was increased by the
presence of cTnI1–32(S23D,S24D); but, in the same ternary complex
containing cNTnC(L29Q), the presence of cTnI1–32(S23D,S24D) had no
structural effect. The increased AB inter-helical angle of cNTnC in the
presence of cTnI1–32(S23D,S24D) versus cTnI1–32 suggests that when
cTnI1–32 is phosphorylated cNTnC is more closed and therefore is
less likely to bind cTnI147–163 and promote contraction. Contrariwise,
the lack of a change in the conformation of cNTnC(L29Q) between
cTnI1–32 and cTnI1–32(S23D,S24D) suggests that the L29Q mutation ren-
ders cTnC insensitive to this type of structural regulatory mecha-
nism. The chemical shift data from our study, on the other hand, do
not indicate a signiﬁcant structural perturbation (as indicated by a
change in the AB or CD inter-helical angles) induced by the N-
terminus of cTnI, either upon binding cNTnC or cNTnC(L29Q)
(Table 1). The peptide used in our study spans residues 1–29 and al-
though this has been shown to theminimal length of cTnI required to
elicit its modulatory role [75], it is possible that the extra residues
not included in our work are necessary for the full structural effect
of cTnI1–32. However, a recent study of cTnC bound to cTnI1–73, has
indicated that the presence of the N-terminus of cTnI does not
cause a structural perturbation of cNTnC [74]. So, it seems likely
that cTnI1–32 alters contractility not through direct modulation of
the conformation of cNTnC, but by another mechanism.
The NMR structure of cTnI1–32 [76] was recently used to construct a
model of the interaction between cNTnC and cTnI1–32 [77,78]. Although,
it is likely that theN-terminus of cTnI does not bind to cNTnC in one sin-
gle conformation [74], themodel nevertheless provides utility in the in-
terpretation of the wider structural implications of the L29Q mutation.
In Fig. 7 we have superimposed the NMR structures of cNTnC (Fig. 7A)
and cNTnC(L29Q) (Fig. 7B) with coordinates depicting the interaction
between cNTnC and cTnI1–32. The model indicates that the site 1 loop
from cNTnC(L29Q) clashes with backbone residues of cTnI1–32. This ste-
ric clash may explain the reduced afﬁnity of the N-terminus of cTnI for
cNTnC(L29Q) [24,32]. Other explanations for the reduced afﬁnity of
cTnI1–32 for cNTnC(L29Q) may be the increased ﬂexibility or decreased
hydrophobicity of Q29, either of which could lead to a destabilization of
the binding site(s) of cTnI1–32. Consequently, it is possible that the
change in the conformation, dynamics and/or polarity of loop 1
contribute(s) to the pathogenesis of the L29Q mutation by impairing
the cNTnC(L29Q)-cTnI1–32 interaction.
Our previous work showed that cNTnC moved towards the N-
terminal region of cTnI during heart muscle activation, and that active
force-generating myosin heads enhanced this structural transition
[58]. In thatmodel, themovement of cNTnCwould enable its interaction
with cTnI1–32 and pull the C-terminal region of cTnI (cCTnI) away from
its actin-binding site. In addition, binding of myosin to actin during
Ca2+ activation would suppress the return of cCTnI to its actin-
binding site by stabilizing tropomyosin away from its initial inhibitory
position, consequently facilitating themovement of cNTnC and its inter-
action with cTnI1–32. The present results suggest that this interaction is
linked to the cooperative activation of the heart muscle and its Ca2+
sensitivity. Inhibition of active force by blebbistatin, on the other hand,
would reduce the interaction between cNTnC and cTnI1–32 and, accord-
ing to this hypothesis, the associated changes in cooperativity and Ca2+
sensitivity.
The weakening of the interaction between cNTnC and cTnI1–32 by
the L29Q mutation seen in previous studies might therefore act by
weakening its stabilizing effect on the active state, associated with the
decrease of cooperativity and Ca2+ sensitivity. However, the decrease
in Ca2+ sensitivity produced by the TnI interaction seems to be compen-
sated for by a local effect on Ca2+ afﬁnity, which would account for our
ﬁnding that the L29Qmutation has no net effect on the Ca2+ sensitivity
of the structural changes in cTnC. On the other hand, the effect of the
L29Q mutation on the structural changes in cTnC associated with
force-generating myosin heads would have a profound impact on the
cardiac function. Since the myoﬁlament response to force-generating
myosin heads is an important regulatory mechanism in cardiac muscle
contraction, the lack of this coupling in the presence of L29Q mutation
in cTnC could contribute to its pathogenesis in FHC.
5. Conclusion
In this study we use a variety of structural and functional tech-
niques to shed light on the effect of the FHC-related L29Q mutation
in cTnC. Our NMR spectroscopy data for the structure of the Ca2+-
bound cNTnC(L29Q) revealed that the overall structure was unper-
turbed by the mutation, although some small local changes were ob-
served which translate to a slight decrease in protein stability. Our in
situ polarized ﬂuorescence results from heart muscle cells showed
that, although the L29Qmutation did not affect the overall amplitude
and Ca2+-sensitivity of the cTnC structural changes, it decreased
their cooperativity. Furthermore, the L29Q mutation abolished the
effect of force-generating cross-bridges on the Ca2+ sensitivity of
the structural changes, which could contribute to the pathogenesis
of FHC. This type of multidisciplinary structural study will be crucial
in the future to construct a structural and functional paradigm for the
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